Development of Hematopoietic Growth Factors for Use in Military Personnel
Status rept. 1 Oct 1990-28 Feb 1991
NEW ENGLAND DEACONESS HOSPITAL BOSTON MA
Pagination or Media Count:
In order to focus on the putative active site of erythropoietin more carefully, we have begun to develop a series of single amino acid substitution mutants. Since our last report we have succeeded in deriving five new mutants, with six more to be produced. The mutants already in hand are currently being subjected to DNA sequencing to confirm their structure, and within the next two to three months the cDNAs will be transfected into the mammalian cells and the specific activity of these mutants will be assessed. Although not previously proposed, we have obtained a series of monoclonal antibodies through collaboration with investigators at the Incstar Corporation in Minnesota. These antibodies are directed toward the 99-129 amino acid sequence of erythropoietin. We have found that these antibodies recognize specific features of the hormones active site differentially.
- Medicine and Medical Research